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Abstract
Radiation therapy is a widely used therapeutic approach for cancer. To improve the efficacy of radiotherapy there
is an intense interest in combining this modality with two broad classes of compounds, radiosensitizers and
radioprotectors. These either enhance tumour-killing efficacy or mitigate damage to surrounding non-malignant
tissue, respectively. Radiation exposure often results in the formation of DNA double-strand breaks, which are
marked by the induction of H2AX phosphorylation to generate gH2AX. In addition to its essential role in DDR
signalling and coordination of double-strand break repair, the ability to visualize and quantitate gH2AX foci using
immunofluorescence microscopy techniques enables it to be exploited as an indicator of therapeutic efficacy in a
range of cell types and tissues. This review will explore the emerging applicability of gH2AX as a marker for
monitoring the effectiveness of radiation-modifying compounds.
Introduction
Radiotherapy is widely used for the management of can-
cer and relies on ionizing radiation (IR)-induced DNA
damage to kill malignant cells. DNA double-strand
breaks (DSBs), which are exceptionally lethal lesions can
be formed either by direct energy deposition or indir-
ectly through the radiolysis of water molecules, which
generate clusters of reactive oxygen species that attack
DNA molecules [1-4]. DSBs are essentially two single-
stranded nicks in opposing DNA strands that occur in
close proximity, severely compromising genomic stabi-
lity [2,5-7]. Therefore, it is critical that DSBs are
repaired quickly and efficiently to prevent cellular death,
chromosomal aberrations and mutations [6,8]. A series
of complex pathways collectively known as the DNA
damage response (DDR) is responsible for the recogni-
tion, signalling and repair of DSBs in cells, ultimately
resulting in either cell survival or cell death [9,10]. DSBs
are repaired by two major pathways, homologous
recombination (HR) or non-homologous end joining
(NHEJ), each with distinct and overlapping roles in
maintaining genomic integrity. NHEJ, the more error-
prone pathway, is commonly employed following IR-
induced damage [11]. IR-induced DSBs cause rapid
phosphorylation of the histone H2A variant H2AX to
form gH2AX. This phosphorylation event takes place at
the highly conserved SQ motif, which is a common sub-
strate for the phosphatidyl-inosito 3-kinase (PI3K)
family of proteins including ataxia telangiectasia mutated
(ATM) [12-16]. Discrete nuclear foci that form as a result
of H2AX phosphorylation are now widely used as a sensi-
tive and reliable marker of DSBs [17,18]. Following a dis-
cussion of the biology of gH2AX formation, this review
will focus on the utility of gH2AX as a molecular marker
for monitoring the efficacy of radiation-modifying
compounds.
Radiation-induced gH2AX formation
Recent years have witnessed a remarkable proliferation in
immunofluorescence-based assays dedicated to the visua-
lization of gH2AX foci. This has emerged as the preferred
method of DSB detection given that 20-40 DSBs are esti-
mated to form per Gray of g-radiation [17,18]. Due to its
high sensitivity, DSBs can be distinguished at clinically
relevant doses, unlike previous methods which required
l y s i sa th i g ht e m p e r a t u r e so rl a r g ed o s e so fI R( 5 - 5 0 G y ) ,
which are well above biologically relevant doses [19,20].
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poral and spatial distribution of DSB formation and can
be detected just minutes after g-radiation, reaching a
peak between 30-60 minutes post-irradiation and typi-
cally returning to background levels (at relatively lower
doses) within 24 hours [2,21]. Comparisons of foci num-
bers in irradiated or treated samples are made in compar-
ison to appropriate controls and background levels in the
cell lines of interest. Interestingly, embryonic stem cells
have very high intrinsic levels of gH2AX (more than
100 foci per nucleus) compared to cancer lines (typically
5-20 foci per nucleus) and normal cell lines (typically 1
or 2 foci per nucleus) [22-24]. The characteristics of
gH2AX formation have been most widely investigated in
the context of g-radiation-induced DNA double-strand
breaks, however, gH2AX has also been evaluated follow-
ing irradiation with high linear energy-transfer (LET)
radiations, such as a-particles and heavy ions [25-30].
The gH2AX staining patterns and kinetics observed with
high LET radiation differ significantly compared to those
from g-rays, with the major observations being clusters of
foci along the ion track that typically exhibit prolonged
repair kinetics [30].
Apart from immunofluorescence, Western blotting has
also been suggested as another possible method of eval-
uating the gH2AX response to IR exposure. Data from
our laboratory and others have demonstrated that
although Western blotting is able to detect the presence
of protein in chromatin extracts, it is disadvantaged by
the fact that apoptotic cells express extremely high
levels of gH2AX, as assessed by immunofluorescence,
making it impossible to distinguish between the gH2AX
responses of live cells and apoptotic cells [31]. Further-
more, it is very difficult to accurately detect the discrete
differences that are typically observed, particularly when
the effects of radiation-modifying compounds are being
investigated.
Given its unique sensitivity and specificity, immuno-
fluorescence-based detection of foci formation can
potentially act as an accurate biodosimeter for exposure
to IR following radiation therapy in cancer patients and
is a minimally invasive method that requires only the
collection of peripheral blood lymphocytes or skin biop-
sies [32,33]. Assays of gH2AX foci numbers can serve as
an indication of the efficacy of various cancer therapies
as well as aid in the observation of individual patient
radiosensitivities and responses to specific radiation-
modifying agents [34-36]. It is important to note,
however, that scoring individual gH2AX foci is most
accurate at doses below 4Gy (unless DSB repair, for
example, 24 hours after irradiation, is being investigated
in which cases much higher doses can be examined).
When examining initial damage gH2AX foci typically
overlap above 4 Gy, as has been shown in our laboratory
and others [37]. Methods involving quantitation of total
nuclear fluorescence have been employed for monitoring
gH2AX formation at higher doses.
gH2AX foci form preferentially in euchromatin
One striking observation about gH2AX is that foci are
rarely detected at heterochromatic sites, which typically
demonstrate resistance to IR-induced gH2AX foci for-
mation in spite of heterochromatin’s rich DNA content
[38-41]. Chromatin immunoprecipitation (ChIP) analysis
revealed that transcriptionally silent heterochromatic
regions are resistant to gH2AX accumulation in both
mammalian and yeast cells [38,42]. gH2AX foci distribu-
tion within irradiated cells is uneven as foci can only be
detected at the periphery of heterochromatic regions
rather than within them, the boundaries of which are
maintained by methylation of lysine at position 9 on his-
tone H3 (H3K9), an important epigenomic imprint of
heterochromatic regions [43,44]. The noticeable lack of
H2AX phosphorylation within heterochromatic regions
m a yb ea t t r i b u t a b l et ol o w e rv u l n e r a b i l i t yo fc o m p a c t e d
DNA to DSB induction, migration of DSBs to the per-
iphery, lower amounts of available H2AX, or possible
epigenetic mechanisms that operate in the region to
restrict the accessibility of kinases responsible for H2AX
phosphorylation [40]. Epigenetic mechanisms appear to
be the best possible explanation for the refractory nature
of heterochromatin to gH2AX generation as histone
deacetylase inhibitors (HDACi) have been shown to
influence chromatin reorganisation, forcing the move-
ment of DSBs to the periphery of heterochromatic
regions [38,45]. Another probability could be that
gH2AX foci are epigenetically shielded by loss of hetero-
chromatin features and local chromatin decondensation
at DSB sites [46]. With respect to radiomodification,
numerous emerging compounds, such as the HDACi
discussed below, alter chromatin architecture. Therefore,
the use of gH2AX as molecular marker of DSBs in com-
bination with epigenetic markers of euchromatin and
heterochromatin would allow correlation of radiomodifi-
cation and changes in chromatin landscape when inves-
tigating relevant compounds.
Radioprotection
One of the major hurdles with respect to radiotherapy
use is the preservation of normal tissue while still ensur-
ing the effective killing of tumour cells. Hence, the
radiation dose must be limited by the tolerance of non-
tumour cells to minimise toxicity to normal, healthy tis-
sue [47]. The issue of therapeutic efficacy has been an
important one to address, bringing about the identifica-
tion and development of compounds such as radiosensi-
tizers and radioprotectors, which either sensitize tumour
cells to IR or protect normal cells, respectively [47].
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agents is useful in improving therapeutic gain while
reducing unintended collateral damage to surrounding
normal tissue. Here we discuss, two classes of com-
monly investigated radioprotectors, the free radical sca-
vengers including amifostine and tempol and the
emerging DNA minor groove binding radioprotectors.
Among the first radioprotectors discovered were the
sulfhydryl compounds in the early 1950s [48,49].
Amifostine (WR-2721) is a well-characterised radiopro-
tector approved by the US Food and Drug Administra-
tion (USFDA) for the reduction of cisplatin-induced
cumulative renal toxicity in ovarian cancer patients and
xerostomia in head and neck cancer patients [50,51].
Amifostine is a thiol that confers radioprotection against
the toxicity associated with radiation without reducing
t h ee f f i c a c yo fr a d i o t h e r a p y due to its ability to selec-
tively scavenge radiation-induced radical oxygen species
(ROS) before they harm the vulnerable DNA of normal
cells [52-54]. Although the extent of radioprotection
varies in different tissues, amifostine has broad-spectrum
properties that protect non-tumour cells originating
from almost all tissue types [50,53-55]. Its selectivity for
normal tissue is due to its preferential accumulation in
normal tissue compared to the hypoxic environment of
tumour tissues with low pH and low alkaline phospha-
tase, which is required to dephosphorylate and activate
amifostine [56,57]. The active metabolite, WR-1065 sca-
venges free radicals and is oxidised, causing anoxia or
t h er a p i dc o n s u m p t i o no fo x y g e ni nt i s s u e s[ 5 8 ] .
Amifostine may also cause chromatin compaction, redu-
cing possible sites for ROS activity, thus reducing dou-
ble strand break (DSB) induction as well as increasing
DNA repair and cellular proliferation to aid in the
recovery of damaged cells [50]. Maximal radioprotection
is observed when amifostine is administered within half
an hour before radiation exposure [59,60]. Interestingly,
it has been shown that the radioprotective properties of
amifostine correlated with a reduction in gH2AX foci in
human microvascular endothelial cells [61]. However,
this same paper called the use of gH2AX as molecular
marker for evaluating the efficacy of radioprotectors
into question since the antioxidants N-acetyl-l-cysteine,
captopril and mesna protected from radiation-induced
gH2AX formation but did not exhibit radioprotective
properties by clonogenic survival [61].
Tempol (4-hydroxy-2,2,6,6-tetramethyl-piperidinyloxy)
belongs to a class of water-soluble nitroxides which are
membrane-permeable stable free radical compounds that
confer protection against radiation-induced damage
[62-64]. It is thought to elicit its effects through the oxi-
dation of reduced transition metals, scavenging free radi-
cals and mimicking superoxide dismutase activity [63,65].
In vitro studies have shown that tempol has dose-
dependent radioprotective properties which are more
efficacious in aerobic conditions as compared to hypoxic
environments [66]. Tempol is capable of protecting cells
from the mutagenic effects of oxy radicals, aminoxyls and
nitroxyls, decreases X-ray induced DSB frequency, and
reduces the number of chromosomal aberrations in
human peripheral blood cells [67-69]. These findings
were also observed in vivo and tempol was shown to be
specific for non-tumour cells, which may be attributable
to the lack of oxygen or high levels of bioreduction
occurring in tumour cells [70]. However, these effects are
observed only if tempol is administered immediately
before radiation exposure [71]. Interestingly, gH2AX has
been employed as a molecular marker to evaluate the
effects of tempol in the context of radiation-induced
bystander effect [72]. Tempol was found to reduce
gH2AX formation in normal human fibroblasts that were
exposed to media from UVC-irradiated cells [72].
The DNA minor groove binding bibenzimidazoles
represent a different class of potential radioprotectors.
Essentially, this group of experimental compounds can
be considered as DNA antioxidants that display much
greater potency than amifostine and tempol in cell cul-
ture systems [73]. DNA minor groove binding radiopro-
tectors are exemplified by the commercially available
and widely used DNA stain, Hoechst 33342. Hoechst
33342 binds tightly in the minor groove of DNA predo-
minantly in regions containing four consecutive AATT
base pairs [74,75]. The compound is utilised extensively
in flow cytometric studies due to its intrinsic fluores-
cence properties which become amplified once the
ligand is bound to DNA. In the early 1980s Hoechst
33342 was shown to possess radioprotective properties
which have been subsequently investigated in cell cul-
ture systems and in vivo [73,76-82]. Synthetic chemistry
was employed to improve the radioprotective properties
of Hoechst 33342 leading to the development of the
potent analogues, proamine and methylproamine
[73,77,78]. Cell culture studies using conventional clono-
genic survival assays indicate that methylproamine is the
most potent of the three analogues [73]. Recently,
gH2AX has been used to further evaluate the radiopro-
tective properties of this compound [83,84]. Studies
have indicated that methylproamine protects cells from
initial DNA damage following ionizing radiation [83,84].
In accordance, it was identified, using gH2AX as a mole-
cular marker of DSBs, that cells must be pretreated with
the compound for radioprotection [83,84]. In summary,
gH2AX has emerged as particularly useful marker for
evaluating the effects of compounds that protect cells
from the effects of ionizing radiation and can provide
further insights into radioprotective mechanisms.
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Radiosensitizers enhance the sensitivity of cells to radia-
tion. For example, numerous conventional chemothera-
peutics, such as bleomycin, etoposide and the
anthracyclines are known to sensitize cells to the effects
of ionizing radiation. Doxorubicin is a frontline anti-
cancer chemotherapeutic anthracycline which elicits its
cytotoxicity through the inhibition of DNA synthesis
and DNA topoisomerase II enzymes, chromatin modula-
tion and generation of highly reactive free radicals
[85-88]. Tumour resistance and toxicity to normal tis-
sues, especially cardiotoxicity, are major issues in rela-
tion to the use of this compound [85]. When combined
with radiation, doxorubicin enhances radiosensitivity,
especially when administered 4 hours before irradiation
[89]. Further evidence of this synergistic effect is high-
lighted in a clinical study where the combination of
radiation and doxorubicin increased response rates and
longer remission periods in patients with squamous cell
carcinoma of the esophagus, thus increasing patient sur-
vival rates [90]. With respect to induction of DSBs and
gH2AX, the cytotoxicity of doxorubicin has been widely
investigated using this molecular marker. Indeed, one
particular study indicated that gH2AX may be used as
surrogate marker for clonogenic death induced by dox-
orubicin and other DSB-inducing genotoxic agents [91].
A recent study has employed gH2AX foci formation to
evaluate the DSB-inducing effects of doxorubicin in nor-
mal cell cardiomyocytes when used alone and in combi-
nation with the HDAC inhibitor Trichostatin A [92].
With respect to combinations of doxorubicin and radio-
therapy, an interesting recent finding suggests that low
doses of ionizing radiation may suppress doxorubicin-
induced senescence as indicated by inhibiting phosphor-
ylation of p38 MAP kinase and p53 [93]. The findings
indicated that gH2AX levels remained unchanged
prompting the authors to conclude that suppression of
doxorubicin-induced senescence was not associated with
genotoxic damage [93]. In this study, cells were exposed
to doxorubicin four hours after low dose (up to 0.2 Gy)
ionizing radiation [93]. Overall, these findings highlight
the utility of gH2AX as molecular marker for delineating
the combinatorial effects of genotoxic agents and ioniz-
ing radiation.
Apart from the classical chemotherapeutics, emerging
more selective anti-cancer therapeutics are displaying
synergistic, or at least additive effects with ionizing
radiation. For example, inhibitors of the DNA damage
repair enzyme, poly(ADP-ribose) polymerase (PARP)
have been shown to suppress resistance to chemother-
apy and to enhance the cytotoxic effects of ionizing
radiation [94,95]. PARP inhibitors are particularly effec-
tive in targeting cancer cells with mutations in the
BRCA1 and BRCA2 tumour suppressor genes [96,97].
Therefore, a number of PARP-inhibiting analogues are
currently undergoing clinical trials for BRCA1 and
BRCA2 negative advanced breast and ovarian cancers as
well as BRCA2 negative prostate cancer [98,99]. BRCA1
and BRCA2 are both implicated in maintaining genomic
integrity, at least in part, by their involvement in DNA
repair providing a rationale for the effectiveness of
PARP inhibitors in malignancies with mutations in these
genes [100,101]. Given that PARP inhibitors alter DNA
repair, gH2AX has been used as a biomarker for evalua-
tion of the efficacy of these compounds, particularly in
combination with other therapeutics, in cancer cell lines
[102,103]. Further, gH2AX foci formation has been used
to evaluate the combined effects of PARP inhibitors and
radiation [94,104]. An exciting new direction is the
potential of utilizing poly(ADP-ribosylation) and gH2AX
as biomarkers to monitor the effects of PARP inhibitors
and combination therapies in clinical samples. This pro-
spect is analysed thoroughly in a recent review [105].
Another, emerging class of potential radiation-
modifying compounds that will be discussed is the
HDACi. The use of HDAC inhibitors combined with
radiation dates back to the 1980s when sodium butyrate
was found to potentiate radiosensitivity in cultured cells
in vitro [106-108]. Several HDAC inhibitors have since
proceeded to clinical trials and the USFDA recently
approved the use of suberoylanilide hydroxamic acid
(SAHA or Vorinostat) for the treatment of cutaneous
T-cell lymphoma (CTCL) [109,110]. The molecular
mechanisms of action of HDAC inhibitors in enhancing
radiation-induced cytotoxicity is thought to involve the
transcriptional regulation of genes and impairment of
DNA repair processes through the accumulation of
acetyl groups on histone and non-histone substrates
[109,111-117]. The repression of DDR proteins includ-
ing ATM, DNA protein kinase catalytic subunit (DNA-
PKcs), Rad52, Rad51, p53-binding protein 1 (53BP1)
and the tumour suppressor breast cancer 1 (BRCA1) is
thought to contribute to cell-killing capacity of HDAC
inhibitors [117-121]. Additionally, chromatin remodel-
ling due to HDAC inhibitor-mediated hyperacetylation
may inhibit the function of histone deacetylases
(HDACs) in the late stages of DNA repair when chro-
matin is restored to its original state [122]. Another
effect of HDAC inhibitor-mediated chromatin remodel-
ling is the generation of a less compacted, relatively
open chromatin structure which is more vulnerable to
radiation damage [123].
Numerous studies involving radiosensitizers such as
HDAC inhibitors have used gH2AX as a marker of
radiosensitization [121,124-126]. One study investigating
the radiosensitizing effects of Trichostatin A (TSA)
found that erythroleukemic cell survival was reduced by
over 60% when TSA was administered 24 hours prior to
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cells to radiation. This coincided with a significant
increase in preferential euchromatic formation of
gH2AX [38,123]. Other studies support this finding,
reporting similar observations in glioblastoma cell lines
and non-small cell lung cancer cell lines, with a dose-
dependent reduction in cell survival and enhanced
gH2AX expression [127,128]. Similar findings were
observed with other HDAC inhibitors including SAHA,
valproic acid and butyric acid [121,126,129-132]. Nota-
bly, tumour cells are more susceptible to the cytotoxic
effects of HDAC inhibitors compared to normal cells,
an important feature of an efficient radiosensitizer [133].
The radiation sensitizing properties of TSA as assessed
by gH2AX immunofluorescence are highlighted in
Figure 1. These findings are an extension of our pre-
viously published chromatin immunoprecipitation stu-
dies which highlight the radiation-sensitizing effects the
histone deacetylase inhibitor in K562 cells [134].
Paradoxically, HDAC inhibitors have also been shown
to possess radioprotective properties. Treatment of cells
in vitro with phenylbutyrate showed higher clonogenic
survival of normal cells which correlated with lower
gH2AX foci numbers after radiation exposure, indicating
that HDAC inhibitors may reduce radiation damage in
normal cells [125]. Phenylbutyrate conferred protection
of non-tumour cells against chemically induced oral car-
cinogenesis and oral mucositis, both severe unwanted
side effects of radiation [125].
A well-known issue in radiation oncology is the rela-
tive radioresistance of hypoxic cells that exist within
solid tumors compared to normoxic malignant cells.
Attempts to circumvent the problem associated with tis-
sue hypoxia in radiotherapy include the evaluation of
radiation sensitizers, particularly nitroimidazoles, a prac-
tise which dates back several decades [135,136].
Numeorus compounds have been identified and evalu-
ated as potential radiosensitisers of hypoxic cells includ-
ing convetional anticancer chemotherapeutics,
bioreductive agents and inhibitors of hypoxia-inducible
factor-1 (HIF-1) as reviewed recently [137]. Evaluation
of DNA damage using gH2AX as a molecular marker
has been employed both in cell culture and in vivo stu-
dies, to investigate the efficacy of compounds including
PX-478 (an HIF-1a inhibitor), nitric oxide (thought to
react with free radicals on the DNA), etoposide (classical
B
A
Figure 1 Trichostatin A enhances radiation-induced gH2AX foci formation in K562 cells. Cells were pre-treated with the indicated
concentrations of Trichostatin A for 24 hours prior to irradiation (2 Gy,
137Cs). Cells were fixed and stained for gH2AX analysis 1 hour after
irradiation. Images were acquired with a Zeiss LSM 510 meta confocal microscope using 0.5 μmz ‐sectioning (63x oil immersion objective). The
number of gH2AX foci per nucleus was quantitated using ImageJ (Fiji). Mean ± standard deviations are indicated, *** p < 0.001 (A). Images were
exported as TIFF files using Metamorph software for immunofluorescence visualization of nuclei (TO-PRO-3, blue) and gH2AX foci (green). For
comparison cells treated with 2 Gy alone (i and ii) and cells exposed to 0.5 μM Trichostatin A prior to 2 Gy irradiation (iii and iv) are shown (B).
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hypoxic cell targeting bioreductive cytotoxin) [138-142].
Apart from being a useful marker for the evaluation of
the efficacy of radiosensitizers of hypoxic cells, it is
noteworthy that a seminal study has identified the criti-
cal role of gH2AX and therefore, by extrapolation of the
DNA damage response, in hypoxia-induced neovascular-
ization in endothelial cells [143].
In vivo gH2AX models
Overall the in vitro studies with radiation protective and
radiosensitizing compounds to date highlight the utility
of quantitating gH2AX foci as means of examining the
efficacy of radiation-modulating compounds in vitro as
it produces results that, more often than not reflect,
data from clonogenic cell survival assays. However,
in vivo studies to determine the efficacies of radiation-
modifying compounds are critical before advancing to
preclinical and clinical trials. Radiation therapy results
in various tissue-specific effects which can be monitored
in vivo through a variety of radiobiological models.
Among the most well-characterised models are
erythema, edema and moist desquamation when the epi-
dermis is exposed to sub-lethal doses of radiation
[144,145]. Maximal levels of moist desquamation occur
at 20 days post-irradiation, while erythema and edema
peak a day or two following radiation exposure [145].
Radiation injury can also be detected using murine colo-
nic mucosal studies as the radiosensitivity of colonic
mucosal cells reflects the radiosensitivity of other cells
of epithelial origin [146]. Given that the colonic mucosa
possesses regeneration capacity, its recovery from radia-
tion injury is a good indicator of the effects of radiation
in vivo [146]. Another well-established mouse tongue
model has been used for studying radiobiological studies
on oral mucositis since the early 1990s [147,148]. Oral
mucositis is an adverse complication associated with
radiotherapy of head and neck cancers. The mouse ton-
gue model allows the evaluation of prophylactic and
therapeutic approaches to treatment of oral mucositis
[59]. In this model, radiation-induced changes of the
mouse tongue epithelium are scored on a daily basis
from the onset of first symptoms such as erosions and
ulcerations until complete repopulation of the epithe-
lium [148,149].
The models outlined above are well-established and
suitable for the monitoring of tissue responses over spe-
cified durations however, a major limitation is the need
to monitor tissue responses over protracted time peri-
ods. Evaluation of gH2AX in vivo is emerging as a pro-
mising alternative with many studies demonstrating its
exquisite sensitivity and reliability [150-152]. Several stu-
dies have deduced that gH2AX is a useful indicator for
investigating the response of normal and tumour tissues
to irradiation as well as for the prediction of individual
responses to radiation therapy [150-152]. The immuno-
fluorescence assay has been applied to evaluate DNA
damage following irradiation in a range of cell types and
tissues, including peripheral blood lymphocytes, skin
biopsies and thymic tissues [153-155]. In an interesting
recent study, a radiation dose-dependent increase in
gH2AX foci was observed in exfoliated buccal mucosal
cells following radiation [150]. Given the significance of
buccal mucosal cell injury in radiation-induced xerosto-
mia, this model may be suitable for adaptation for the
evaluation of potential radiation modifying compounds.
Similarly, a recent model indicates the predictive nature
of quantitating gH2AX in murine skin following radia-
tion [151]. It was identified that residual foci, 10 days
after irradiation, may be the most accurate for determin-
ing radiosensitivity [151]. Again, given the clinical pro-
blems associated with radiation-induced skin injury,
adaptation of this model may provide a means for evalu-
ating the effects of radiomodifiers. However, largely to
difficulties in establishing dose-responses that accurately
depict radiosensitivity in different cell types and with
issues with quantitating gH2AX foci in various cell types
in tissue sections (typically 5-8 μm sections and up to
20 μm), widespread use of in vivo models for evaluating
the effects of radiation-modifying compounds is still
limited.
High through-put screening
The gH2AX immunofluorescence-based assay is cur-
rently the most sensitive and robust method for detect-
ing DSBs, prompting research into the development of
automated methods to expedite processing and analysis
of gH2AX foci [156]. This field is progressing steadily,
with developments including automated specimen pre-
paration and computerised image acquisition, digital
analysis and computer-based algorithms [153,157,158].
Recently, an automated 96-well immunohistochemistry
and microscopy system was unveiled, which can increase
the efficiency of gH2AX analysis with reproducible
results that correspond to those obtained manually, and
could potentially be adapted for high-throughput appli-
cations [159].
Large-scale radiological events and the development
of new radiopharmaceuticals that modulate radiation
sensitivity call for high throughput biodosimetry, utilis-
ing gH2AX as a biomarker of DNA damage. Several
groups have addressed the need for high throughput
evaluation of gH2AX, and one notable advance in this
field is the design of an automated system known as
RABIT (Rapid Automated Biodosimetry Tool), based on
the well-established gH2AX immunofluorescence assay
[160]. Peripheral blood mononuclear cells are easily
obtained with minimal invasion, have very low levels of
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variations, validating its use as a tissue sample for
damage detection following radiation exposure
[19,161,162]. Optimisations are still under way with the
development of the RABIT system and its completion
will provide a significant boost for the assessment of
radiation exposure in humans as well as for monitoring
the efficacy of existing and potential radiation-modifying
compounds.
Conclusions
In summary, gH2AX is a widely used molecular marker
for monitoring the efficacy of radiation-modifying com-
pounds in vitro. However, the assay has not yet sur-
passed the traditional radiobiological models for
preclinical studies with radiation-modifying compounds.
On the basis of its popularity in the detection of radia-
tion-induced DNA damage in cell culture studies, and
given its reproducibility and reliability, the immuno-
fluorescence assay is likely to become more widely
employed in vivo. It is expected that with advances in
3D imaging and analysis, superior predictive models of
t i s s u ed a m a g eb a s e do ngH2AX will be established.
Finally, it would be a major accomplishment if the assay
can be adapted for high-throughput evaluation.
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